Development of a hammerhead ribozyme against BCL-2. II. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents

Anticancer Research

Volumn 17, Issue 5 A, 1997, Pages 3307-3312

  Dorai, Thambi ^a   Goluboff, Erik T ^a   Olsson, Carl A ^a   Buttyan, Ralph ^a  

^a Atchley Pavilion 11 ^*  (United States)

Author keywords

Bcl 2; Gene therapy; Hormone resistance; Prostate cancer; Ribozyme

Indexed keywords

COMPLEMENTARY RNA; MESSENGER RNA; PHORBOL ESTER; PROTEIN BCL 2; RIBONUCLEASE; RIBOZYME;

APOPTOSIS; ARTICLE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER;

APOPTOSIS; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH INHIBITORS; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, CATALYTIC; RNA, VIRAL; TUMOR CELLS, CULTURED;

EID: 0030830717     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Haseloff J and Gerlach WJ: Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature (London) 334: 585-591, 1988.
2. Cech TR: Ribozymes and their medical implications. J Am, Med Assoc 260: 3030-3034, 1988.
3. Ohkawa J, Koguma T, Kohda T and Taira K.Ribozymes: From mechanistic to applications in vivo. J Biochem (Tokyo). 118: 251-258, 1995.
4. Kobayashi H, Dorai T, Holland JF and Ohnuma T: Reversal to drug sensitivity in Multidrug Resistant tumor cellsby an MbRI (PGYI) ribozyme. Cancer Res 54: 1271-1275, 1994.
5. Dorai T, Kobayashi H, Holland JF and Ohnuma T: Modulation of the platelet derived growth factor-B mRNA expression and celi growth in a human mesothelioma cell line by a hammerhead ribozyme. Mol Pharmacol 46: 436-444, 1994.
6. Sarver N, Cantin EM, Chang PS, Zaia JA, Ladne PA, Stephens DA and Rossi JJ: Ribozymes as potential anti-HIV-1 therapeutic agents. Science (Washington) 247: 1222-1225, 1990.
7. Dorai T, Olsson CA, Katz AE and Buttyan R: Development of a hammerhead ribozyme against bcl-2I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer. Prostate (In Press).
8. Nunez G, London L, Hockenbery D, Alexander M, McKearn J and Korsmeyer SJ: Deregulated bcl-2 expression selectively prolongs survival of growth factor deprived hematopoietic cell lines: J Immunol 144: 3602-3609, 1990.
9. Korsmeyer SJ: bcl-2 initiates a new category of oncogenes: Regulators of cell death. Blood 80: 879-887, 1992.
10. Batistatou A, Merry DE, Korsmeyer SJ and Green LA: Expression of bcl-2 protooncogene rescues PC12 cells from cell death caused by withdrawal of trophic support. J.Neurosci 13: 4422-4428, 1993.
11. Garcia I, Martinou I, Tsujimoto Y and Marthou JC: Prevention of programmed cell death of sympathetic neurons by the bcl-2 protooncogene. Science (Washington) 258: 302-305, 1992.
12. McDonnell TJ., Troncoso P., Brisbay SM., Logothetis C., Chung LWK., Hsieh J-T., Tu S-M and Campbell ML. Expression of bcl-2 in the prostate and its association with the emergence of androgen independent prostate cancer. Cancer Res 52: 6940-6944, 1992.
13. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M., Olsson CA., Kormeyer SJ and Buttyan R: Detection of the apoptosis suppressing oncoprotein bcl-2 in hormone refractory human prostate cancers.Am J Pathol 143: 390-400, 1993.
14. Shabaik AS, Krajewski S, Burgan A, Krajewski M and Reed JC: bcl-2 protooncogene expression in normal, hyperplastic and neoplastic prostate tissue. J Urol Pathol 3: 17-27, 1995.
15. Raffo AJ, Perlman H, Chen M-W, Day ML, Streitman JS and Buttyan R: Over expression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo: Cancer Res 55: 4438-4445, 1995.
16. Zhong LT, Sarafian T, Kane DJ, Charles AC, Mah SP, Edwards RH and Bredesen DE: bcl-2 inhibits cell death of central neural cells induced by multiple agents. Proc Natl Acad Sci (USA) 90: 4533-4537, 1993.
17. Miyashita T and Reed JC: bcl-2 oncoprotein blocks chemotherapy induced apoptosis in a human leukemia cell line. Blood: 81: 151-159, 1993.
18. Oltvai ZN., Milliman CL and Korsmeyer SJ: bcl-2 heterodimerizes in vivo with a conserved homolog Bax, that accelerates programmed cell death. Cell 74: 609-617, 1993.
19. Yin X-M., Oltvai ZN and Korsmeyer SJ: BH1 and BH2 domains of bcl-2 are required for inhibition of apoptosis and heterodimerization with bax: Nature (London) 369: 321-324, 1994.
20. Crystal RG: Transfer of genes to humans. Early lessons and obstacles to success. Science (Washington) 270: 404-410.